Interview with Joanne Wilson, APRN-NP, DNP: CAR T-Cell Therapy for Solid Tumors

Interview with Joanne Wilson, APRN-NP, DNP: TIL Therapy

Welcome to the CAR T-Cell Therapy Resource Center! Here you’ll find current information, news items, highlights from the literature, case studies, and other resources that focus on CAR T-cell therapies and the advanced practitioner’s role in delivering high-quality care to our patients. If you have any feedback or questions, please contact jadpro-editor@conexiant.com.

Liza Rodriguez, DNP, E-MBA, APRN, AOCNP
APP Manager Hematology/Blood and Marrow Transplant Program
APP Council Chair
Division of Hematologic Malignancies and Cellular Therapeutics
The University of Kansas Cancer Center

Practical Guidance for the Diagnosis and Management of Secondary Hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees

FDA eliminates risk evaluation and mitigation strategies (REMS) for autologous chimeric antigen receptor CAR T-cell immunotherapies

Clinical experience with cranial nerve impairment in the CARTITUDE-1, CARTITUDE-2 cohorts A, B, and C, and CARTITUDE-4 studies of ciltacabtagene autoleucel (cilta-cel)

CAR T-Cell Therapy Resource Center

Interview with Joanne Wilson, APRN-NP, DNP: CAR T-Cell Therapy for Solid Tumors

Practical Guidance for the Diagnosis and Management of Secondary Hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees

ASH-ASTCT COVID-19 Vaccination for HCT and CAR T Cell Recipients: Frequently Asked Questions

CAR T Patient and Caregiver Guide

CAR T-Cell Therapy for Large B-Cell Lymphoma

ASTCT NucleusPlus: Insights on Emerging CAR-T Therapies

Seminars in Arthritis and Rheumatism

Advancing autoimmune rheumatic disease treatment: CAR T-cell therapies—evidence, safety, and future directions

Nature Reviews Immunology

In vivo CAR engineering for immunotherapy

Journal for ImmunoTherapy of Cancer

rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR T-cell therapy in solid tumors

U.S. Food and Drug Administration

FDA eliminates risk evaluation and mitigation strategies (REMS) for autologous chimeric antigen receptor CAR T-cell immunotherapies

Stem Cells Translational Medicine

Anti-viral CD8 central memory veto cells as a new platform for CAR T cell therapy

Journal for ImmunoTherapy of Cancer

Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach

Blood Advances

Inequalities in CAR T-cell therapy access for US patients with relapsed/refractory DLBCL: A SEER-Medicare data analysis

Blood Advances

BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement

Transplantation and Cellular Therapy

Clinical experience with cranial nerve impairment in the CARTITUDE-1, CARTITUDE-2 cohorts A, B, and C, and CARTITUDE-4 studies of ciltacabtagene autoleucel (cilta-cel)

Blood Advances

Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel

Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy in a Patient With Multiple Myeloma

Bloodless Medicine Management of a Patient Receiving CAR T-Cell Therapy

Transverse Myelitis With Paraplegia: An Atypical Manifestation of Neurotoxicity Following CAR T-Cell Therapy

Fast Facts #12: BCMA Targets